Immune-Related Adverse Events for Renal Toxicities - Nephritis
ورودیهای بالینی بیمار
حداقل ۰.۳ — حداکثر ۱۵ • واحد: mg/dL
حداقل ۰.۳ — حداکثر ۳۰ • واحد: mg/dL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Grade 11–1
- Grade 22–2
- Grade 33–3
- Grade 44–4
The Immune-Related Adverse Events for Renal Toxicities - Nephritis calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include baseline creatinine. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Grades severity of nephritis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates serum creatinine levels, renal function changes, and clinical symptoms to determine the severity of immune-mediated nephritis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, nephrology consultation needs, and monitoring for life-threatening renal complications. ICPi-induced nephritis has an incidence of 1-2% in single-agent therapy and 4.5% in combination therapy, with median onset at 14 weeks (range 6.5-21 weeks). The calculator provides evidence-based management recommendations essential for oncologists, nephrologists, and multidisciplinary teams managing patients on immunotherapy.
Clinical Indication
The Immune-Related Adverse Events for Renal Toxicities - Nephritis is indicated for bedside clinical practice to support Grades severity of nephritis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates serum creatinine levels, renal function changes, and clinical symptoms to determine the severity of immune-mediated nephritis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, nephrology consultation needs, and monitoring for life-threatening renal complications. ICPi-induced nephritis has an incidence of 1-2% in single-agent therapy and 4.5% in combination therapy, with median onset at 14 weeks (range 6.5-21 weeks). The calculator provides evidence-based management recommendations essential for oncologists, nephrologists, and multidisciplinary teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care. Clinical exclusion: Consider empiric treatment without biopsy if typical presentation and exclusion of other causes.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Median time to onset: 14 weeks (range 6.5-21 weeks after treatment initiation).
CTCAE grading based on serum creatinine fold increase over baseline: Grade 1: 1.5-2× baseline; Grade 2: 2-3× baseline; Grade 3: >3-6× baseline; Grade 4: >6× baseline OR dialysis required
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| baseline_creatinine | float | Yes | Baseline serum creatinine level in mg/dL before ICPi therapy initiation. Essential reference point for calculating fold increase. Normal range typically 0.6-1.2 mg/dL but varies by age, sex, muscle mass, and laboratory(mg/dL) |
| current_creatinine | float | Yes | Current serum creatinine level in mg/dL. Used to calculate fold increase over baseline for CTCAE grading. Significant elevation indicates renal impairment and possible nephritis(mg/dL) |
| proteinuria_present | string | Yes | Presence of proteinuria on urinalysis or urine protein/creatinine ratio. May indicate glomerular involvement in addition to interstitial nephritis. Important for differential diagnosis and prognosis |
| hematuria_present | string | Yes | Presence of hematuria (blood in urine) on urinalysis. May suggest glomerular disease or more severe nephritis. Important for determining need for kidney biopsy and management approach |
| clinical_symptoms | string | Yes | Presence of clinical symptoms related to nephritis. Asymptomatic: no symptoms, lab changes only. Mild: minimal symptoms not affecting daily activities. Moderate: symptoms interfering with daily activities. Severe: significant symptoms limiting self-care |
| fluid_retention | string | Yes | Evidence of fluid retention including edema, weight gain, or volume overload. May manifest as facial, abdominal, or extremity edema, sudden weight gain, or hypertension. Indicates more severe nephritis |
| dialysis_required | string | Yes | Need for renal replacement therapy (hemodialysis, peritoneal dialysis, or continuous renal replacement therapy). Indicates Grade 4 severity regardless of other parameters. Life-threatening complication |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Grade 1 | Mild - Creatinine 1.5-2× baseline |
| 2–2 | Grade 2 | Moderate - Creatinine 2-3× baseline |
| 3–3 | Grade 3 | Severe - Creatinine >3-6× baseline |
| 4–4 | Grade 4 | Life-threatening - Creatinine >6× baseline OR dialysis required |
Evidence-Based References (EBM)
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.DOI: 10.1200/JCO.2017.77.6385
- Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.DOI: 10.6004/jnccn.2020.0012
- Cortazar FB, Marrone KA, Troxel AB, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008.DOI: 10.1016/j.kint.2016.04.008
- Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. Am J Kidney Dis. 2016 Aug;68(2):287-91. doi: 10.1053/j.ajkd.2016.02.057.DOI: 10.1053/j.ajkd.2016.02.057
Related calculators
- Immune-Related Adverse Events for GI Toxicity - Colitis
- Immune-Related Adverse Events for Lung Toxicity - Pneumonitis
- Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism
- Immune-Related Adverse Events for GI Toxicity - Hepatitis
- Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus